In Vivo Imaging Biomarkers in Mouse Models of Alzheimer's Disease: Are We Lost in Translation or Breaking Through?

Identification of biomarkers of Alzheimer's Disease (AD) is a critical priority to efficiently diagnose the patients, to stage the progression of neurodegeneration in living subjects, and to assess the effects of disease-modifier treatments. This paper addresses the development and usefulness of preclinical neuroimaging biomarkers of AD. It is today possible to image in vivo the brain of small rodents at high resolution and to detect the occurrence of macroscopic/microscopic lesions in these species, as well as of functional alterations reminiscent of AD pathology. We will outline three different types of imaging biomarkers that can be used in AD mouse models: biomarkers with clear translational potential, biomarkers that can serve as in vivo readouts (in particular in the context of drug discovery) exclusively for preclinical research, and finally biomarkers that constitute new tools for fundamental research on AD physiopathogeny

Transmission of amyloid lesions in Alzheimer’s disease: contributing data from animal models

Depuis la découverte du caractère transmissible des maladies à prions, d’autres protéinopathies cérébrales ont été soupçonnées d’être similairement transmissibles. La maladie d’Alzheimer (MA) est caractérisée par des dépôts cérébraux de peptides (Aβ ) et de protéines Tau hyperphosphorylées, respectivement en plaques amyloïdes et dégénérescences neurofibrillaires. Bien qu’aucune étude épidémiologique ne montre que la MA se transmette entre individus, plusieurs études ont récemment soulevé des soupçons de transmission iatrogène des dépôts β-amyloïdes chez l’Homme. Elles suggèrent que le changement de conformation (ou mépliement) de l’Aβ et son agrégation se produit par des mécanismes de nucléation-élongation et de propagation, similaires à ceux décrits pour les maladies à prions. Ici, nous présentons une revue de la littérature démontrant à partir d’études in vivo la pertinence des mécanismes de mépliement et agrégation de type prion pour la pathologie β-amyloïde.Since the discovery of the transmissibility of prion diseases, other cerebral proteinopathies have been suspected to harbor similar transmissible properties. Alzheimer’s disease (AD) is characterized by the deposition of misfolded β-amyloïdes (Aβ ) peptides and hyperphosphorylated Tau proteins, forming amyloid plaques and neurofibrillary tangles respectively in the brain. Although available epidemiological data suggest that AD is not transmitted between individuals, suspicion has recently been raised for iatrogenic β-amyloidosis transmission between humans. This suggests that A b misfolding and aggregation could occur through seeding and spreading mechanisms, virtually identical to those of prions. Here, we present a review of the literature focusing on the relevance of prion-like misfolding and aggregation mechanisms for Aβ in animal models

An evolutionary gap in primate default mode network organization

The human default mode network (DMN) is engaged at rest and in cognitive states such as self-directed thoughts. Interconnected homologous cortical areas in primates constitute a network considered as the equivalent. Here, based on a cross-species comparison of the DMN between humans and non-hominoid primates (macaques, marmosets, and mouse lemurs), we report major dissimilarities in connectivity profiles. Most importantly, the medial prefrontal cortex (mPFC) of non-hominoid primates is poorly engaged with the posterior cingulate cortex (PCC), though strong correlated activity between the human PCC and the mPFC is a key feature of the human DMN. Instead, a fronto-temporal resting-state network involving the mPFC was detected consistently across non-hominoid primate species. These common functional features shared between non-hominoid primates but not with humans suggest a substantial gap in the organization of the primate\u27s DMN and its associated cognitive functions

Voxel-Based Statistical Analysis of 3D Immunostained Tissue Imaging

Recently developed techniques to visualize immunostained tissues in 3D and in large samples have expanded the scope of microscopic investigations at the level of the whole brain. Here, we propose to adapt voxel-based statistical analysis to 3D high-resolution images of the immunostained rodent brain. The proposed approach was first validated with a simulation dataset with known cluster locations. Then, it was applied to characterize the effect of ADAM30, a gene involved in the metabolism of the amyloid precursor protein, in a mouse model of Alzheimer's disease. This work introduces voxel-based analysis of 3D immunostained microscopic brain images and, therefore, opens the door to localized whole-brain exploratory investigation of pathological markers and cellular alterations

Encephalopathy induced by Alzheimer brain inoculation in a non-human primate.

Alzheimer's disease is characterized by cognitive alterations, cerebral atrophy and neuropathological lesions including neuronal loss, accumulation of misfolded and aggregated β-amyloid peptides (Aβ) and tau proteins. Iatrogenic induction of Aβ is suspected in patients exposed to pituitary-derived hormones, dural grafts, or surgical instruments, presumably contaminated with Aβ. Induction of Aβ and tau lesions has been demonstrated in transgenic mice after contamination with Alzheimer's disease brain homogenates, with very limited functional consequences. Unlike rodents, primates naturally express Aβ or tau under normal conditions and attempts to transmit Alzheimer pathology to primates have been made for decades. However, none of earlier studies performed any detailed functional assessments. For the first time we demonstrate long term memory and learning impairments in a non-human primate (Microcebus murinus) following intracerebral injections with Alzheimer human brain extracts. Animals inoculated with Alzheimer brain homogenates displayed progressive cognitive impairments (clinical tests assessing cognitive and motor functions), modifications of neuronal activity (detected by electroencephalography), widespread and progressive cerebral atrophy (in vivo MRI assessing cerebral volume loss using automated voxel-based analysis), neuronal loss in the hippocampus and entorhinal cortex (post mortem stereology). They displayed parenchymal and vascular Aβ depositions and tau lesions for some of them, in regions close to the inoculation sites. Although these lesions were sparse, they were never detected in control animals. Tau-positive animals had the lowest performances in a memory task and displayed the greatest neuronal loss. Our study is timely and important as it is the first one to highlight neuronal and clinical dysfunction following inoculation of Alzheimer's disease brain homogenates in a primate. Clinical signs in a chronic disease such as Alzheimer take a long time to be detectable. Documentation of clinical deterioration and/or dysfunction following intracerebral inoculations with Alzheimer human brain extracts could lead to important new insights about Alzheimer initiation processes

Small-Animal PET Imaging of Amyloid-Beta Plaques with [11C]PiB and Its Multi-Modal Validation in an APP/PS1 Mouse Model of Alzheimer's Disease

In vivo imaging and quantification of amyloid-β plaque (Aβ) burden in small-animal models of Alzheimer's disease (AD) is a valuable tool for translational research such as developing specific imaging markers and monitoring new therapy approaches. Methodological constraints such as image resolution of positron emission tomography (PET) and lack of suitable AD models have limited the feasibility of PET in mice. In this study, we evaluated a feasible protocol for PET imaging of Aβ in mouse brain with [11C]PiB and specific activities commonly used in human studies. In vivo mouse brain MRI for anatomical reference was acquired with a clinical 1.5 T system. A recently characterized APP/PS1 mouse was employed to measure Aβ at different disease stages in homozygous and hemizygous animals. We performed multi-modal cross-validations for the PET results with ex vivo and in vitro methodologies, including regional brain biodistribution, multi-label digital autoradiography, protein quantification with ELISA, fluorescence microscopy, semi-automated histological quantification and radioligand binding assays. Specific [11C]PiB uptake in individual brain regions with Aβ deposition was demonstrated and validated in all animals of the study cohort including homozygous AD animals as young as nine months. Corresponding to the extent of Aβ pathology, old homozygous AD animals (21 months) showed the highest uptake followed by old hemizygous (23 months) and young homozygous mice (9 months). In all AD age groups the cerebellum was shown to be suitable as an intracerebral reference region. PET results were cross-validated and consistent with all applied ex vivo and in vitro methodologies. The results confirm that the experimental setup for non-invasive [11C]PiB imaging of Aβ in the APP/PS1 mice provides a feasible, reproducible and robust protocol for small-animal Aβ imaging. It allows longitudinal imaging studies with follow-up periods of approximately one and a half years and provides a foundation for translational Alzheimer neuroimaging in transgenic mice

Contribution de la Cellule Covid 19 de l'Académie Vétérinaire de France : Bilan provisoire et perspectives

International audienceLa cellule Covid-19 de l'Académie vétérinaire de France a été créée au lendemain de la mise en place du premier confinement lors de la pandémie de 2020 liée au coronavirus SARS-CoV-2. Cette cellule s'est organisée autour de quatre objectifs. 1. Soutenir la participation des vétérinaires à la gestion médicale de la crise. 2. Etayer la compréhension de la Covid-19 à travers la connaissance des coronavirus animaux et des réservoirs de virus. 3. Evaluer le risque de Covid-19 chez les espèces animales. 4. Anticiper les conséquences de cette crise pour la santé animale et la santé publique. La cellule Covid-19 a réalisé de nombreux articles publiés dans le Bulletin de l'Académie Vétérinaire de France ainsi que de nombreux communiqués. Elle a apporté un regard original sur les coronavirus. Elle a aussi souligné des difficultés d'utilisation des ressources vétérinaires par les gestionnaires de la médecine humaine alors qu'en période de crise, toutes les expertises devaient être utilisées. Des corrections devraient être mises en place pour anticiper les futures pandémies